The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be (link sends e-mail)
Study Name on ClinicalTrials.gov (link is external) | Tiotropium Bromide in Cystic Fibrosis |
---|---|
Study Drug | Tiotropium Bromide |
Type of Study Drug | Bronchodilator |
Study Title | A Randomized, Double-blind, Placebo-controlled Parallel Group Study to Investigate the Safety and Efficacy of Two Doses of Tiotropium Bromide (2.5 Mcg and 5 Mcg) Administered Once Daily Via the Respimat Device for 12 Weeks in Patients With Cystic Fibrosis |
Study Phase | 2 |
Study Sponsor | Boehringer Ingelheim Pharmaceuticals |
http://clinicaltrials.gov/ct2/show/NCT00737100 (link is external) | |
Participating ECFS-CTN sites | Study Closed |
Age | Adults and Pediatrics |